NCT05418712

A Microneurography (MNG) Study of VX-150 in Healthy Participants

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating the Effects of VX-150 on C-Nociceptor Action Potentials in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 45 (actual)
• Sponsor: Vertex Pharmaceuticals Incorporated · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine if C fiber conduction is impacted by NAV1.8 modulation.

Detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

Conditions

• Pain

Interventions

Type	Name	Description
DRUG	Placebo	Placebo matched to VX-150 for oral administration.
DRUG	VX-150	Solution or Suspension for oral administration.

Timeline

• Start date: 2022-06-16
• Primary completion: 2022-09-14
• Completion: 2022-09-23
• First posted: 2022-06-14
• Last updated: 2022-10-14

Locations

1 site across 1 country: United Kingdom

Regulatory

• FDA-regulated drug study